328 related articles for article (PubMed ID: 19826357)
1. Progression-free survival is simply a measure of a drug's effect while administered and is not a surrogate for overall survival.
Wilkerson J; Fojo T
Cancer J; 2009; 15(5):379-85. PubMed ID: 19826357
[TBL] [Abstract][Full Text] [Related]
2. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy.
Tang PA; Bentzen SM; Chen EX; Siu LL
J Clin Oncol; 2007 Oct; 25(29):4562-8. PubMed ID: 17876010
[TBL] [Abstract][Full Text] [Related]
3. Overall survival: a gold standard in search of a surrogate: the value of progression-free survival and time to progression as end points of drug efficacy.
Zhuang SH; Xiu L; Elsayed YA
Cancer J; 2009; 15(5):395-400. PubMed ID: 19826359
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer.
Burzykowski T; Buyse M; Piccart-Gebhart MJ; Sledge G; Carmichael J; Lück HJ; Mackey JR; Nabholtz JM; Paridaens R; Biganzoli L; Jassem J; Bontenbal M; Bonneterre J; Chan S; Basaran GA; Therasse P
J Clin Oncol; 2008 Apr; 26(12):1987-92. PubMed ID: 18421050
[TBL] [Abstract][Full Text] [Related]
5. Individual- and trial-level surrogacy in colorectal cancer.
Buyse M; Burzykowski T; Michiels S; Carroll K
Stat Methods Med Res; 2008 Oct; 17(5):467-75. PubMed ID: 18285439
[TBL] [Abstract][Full Text] [Related]
6. Correlation between progression free survival and response rate in patients with metastatic colorectal carcinoma.
Louvet C; de Gramont A; Tournigand C; Artru P; Maindrault-Goebel F; Krulik M
Cancer; 2001 Jun; 91(11):2033-8. PubMed ID: 11391582
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.
Escudier B; Eisen T; Stadler WM; Szczylik C; Oudard S; Staehler M; Negrier S; Chevreau C; Desai AA; Rolland F; Demkow T; Hutson TE; Gore M; Anderson S; Hofilena G; Shan M; Pena C; Lathia C; Bukowski RM
J Clin Oncol; 2009 Jul; 27(20):3312-8. PubMed ID: 19451442
[TBL] [Abstract][Full Text] [Related]
8. Poor correlation between progression-free and overall survival in modern clinical trials: are composite endpoints the answer?
Amir E; Seruga B; Kwong R; Tannock IF; Ocaña A
Eur J Cancer; 2012 Feb; 48(3):385-8. PubMed ID: 22115991
[TBL] [Abstract][Full Text] [Related]
9. Progression-free survival as a surrogate endpoint for median overall survival in metastatic colorectal cancer: literature-based analysis from 50 randomized first-line trials.
Giessen C; Laubender RP; Ankerst DP; Stintzing S; Modest DP; Mansmann U; Heinemann V
Clin Cancer Res; 2013 Jan; 19(1):225-35. PubMed ID: 23149819
[TBL] [Abstract][Full Text] [Related]
10. Poorly differentiated thyroid carcinomas defined on the basis of mitosis and necrosis: a clinicopathologic study of 58 patients.
Hiltzik D; Carlson DL; Tuttle RM; Chuai S; Ishill N; Shaha A; Shah JP; Singh B; Ghossein RA
Cancer; 2006 Mar; 106(6):1286-95. PubMed ID: 16470605
[TBL] [Abstract][Full Text] [Related]
11. Assessment of tumor response as a surrogate endpoint of survival in recurrent/platinum-resistant ovarian carcinoma: a Gynecologic Oncology Group study.
Rose PG; Tian C; Bookman MA
Gynecol Oncol; 2010 May; 117(2):324-9. PubMed ID: 20185168
[TBL] [Abstract][Full Text] [Related]
12. A statistical model for the dependence between progression-free survival and overall survival.
Fleischer F; Gaschler-Markefski B; Bluhmki E
Stat Med; 2009 Sep; 28(21):2669-86. PubMed ID: 19579225
[TBL] [Abstract][Full Text] [Related]
13. Progression-free survival is a surrogate for survival in advanced colorectal cancer.
Buyse M; Burzykowski T; Carroll K; Michiels S; Sargent DJ; Miller LL; Elfring GL; Pignon JP; Piedbois P
J Clin Oncol; 2007 Nov; 25(33):5218-24. PubMed ID: 18024867
[TBL] [Abstract][Full Text] [Related]
14. Overall survival: still the gold standard: why overall survival remains the definitive end point in cancer clinical trials.
Driscoll JJ; Rixe O
Cancer J; 2009; 15(5):401-5. PubMed ID: 19826360
[TBL] [Abstract][Full Text] [Related]
15. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.
Juretzka MM; Barakat RR; Chi DS; Iasonos A; Dupont J; Abu-Rustum NR; Poynor EA; Aghajanian C; Spriggs D; Hensley ML; Sabbatini P
Gynecol Oncol; 2007 Jan; 104(1):176-80. PubMed ID: 16996584
[TBL] [Abstract][Full Text] [Related]
16. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer.
Cohen SJ; Punt CJ; Iannotti N; Saidman BH; Sabbath KD; Gabrail NY; Picus J; Morse M; Mitchell E; Miller MC; Doyle GV; Tissing H; Terstappen LW; Meropol NJ
J Clin Oncol; 2008 Jul; 26(19):3213-21. PubMed ID: 18591556
[TBL] [Abstract][Full Text] [Related]
17. Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals.
Collette L; Burzykowski T; Carroll KJ; Newling D; Morris T; Schröder FH; ; ;
J Clin Oncol; 2005 Sep; 23(25):6139-48. PubMed ID: 16135480
[TBL] [Abstract][Full Text] [Related]
18. A multicenter evaluation of sequential multimodality therapy and clinical outcome for the treatment of advanced endometrial cancer.
Secord AA; Havrilesky LJ; O'Malley DM; Bae-Jump V; Fleming ND; Broadwater G; Cohn DE; Gehrig PA
Gynecol Oncol; 2009 Sep; 114(3):442-7. PubMed ID: 19560193
[TBL] [Abstract][Full Text] [Related]
19. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial.
Trimbos JB; Vergote I; Bolis G; Vermorken JB; Mangioni C; Madronal C; Franchi M; Tateo S; Zanetta G; Scarfone G; Giurgea L; Timmers P; Coens C; Pecorelli S;
J Natl Cancer Inst; 2003 Jan; 95(2):113-25. PubMed ID: 12529344
[TBL] [Abstract][Full Text] [Related]
20. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
